National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Updates to Myelodysplastic Syndromes (MDS) Guidelines

The NCCN Clinical Practice Guidelines in Oncology™ for Myelodysplastic Syndromes (MDS) have been updated and published by the National Comprehensive Cancer Network. The current version is 1.2010.

In the updated version, the category of evidence and consensus for recommending azacytidine for the treatment of higher risk MDS patients (IPSS risk category INTERMEDIATE-2 and High) is now Category 1. Previously, this recommendation was Category 2A. Updates also include the addition of azacytidine, decitabine, or participation in a clinical trial as recommended options for higher risk patients who relapse following allogeneic hemopoietic stem cell transplant.